Researchers have identified a genetic switch that transforms human pancreatic duct cells into insulin-producing beta cells, offering a potential breakthrough for diabetes treatment. By silencing the ALDH3B2 gene, scientists achieved a 8.5% conversion rate in lab experiments, with transplanted cells lowering blood glucose in mice.
A study published in Science Translational Medicine reveals that disrupting the ALDH3B2 gene can convert pancreatic duct cells into functional beta-like cells capable of secreting insulin in response to glucose. This discovery, led by researchers at Harvard Medical School and Joslin Diabetes Center, represents a significant step toward regenerating insulin-producing cells for diabetes therapy.
The Genetic Toggle: From Duct Cells to Beta Cells
The research team used a genome-wide CRISPR screening approach to identify genes regulating the transdifferentiation of pancreatic duct cells into beta cells. They found that loss of function in the ALDH3B2 gene triggered a shift in gene expression toward a beta-cell phenotype. Loss of function of ALDH3B2 transdifferentiates human pancreatic duct cells into β-like cells,
the study states, noting that the converted cells expressed key beta-cell markers and secreted insulin in response to glucose.
Experiments showed that silencing ALDH3B2 increased the proportion of duct cells adopting a beta-cell-like state from less than 1% to approximately 8.5%. When transplanted into diabetic mice, these cells reduced blood glucose levels to near-normal for six weeks. However, the insulin production efficiency remained lower than that of natural human beta cells, highlighting the need for further optimization.
Implications for Diabetes Therapy
Diabetes, a condition marked by inadequate beta-cell function, affects over 830 million people globally. Current treatments rely on insulin injections or transplanted islets, which are limited by donor scarcity. The new approach bypasses the need for external cell sources by reprogramming existing pancreatic cells, offering a scalable solution.
“To cure diabetes, one has to find a way to stop the recurrent autoimmune attack on β cells (type 1 diabetes) or resolve persistent peripheral insulin resistance (type 2 diabetes), but restoring sufficient functional β-cell mass is critical to a cure for both types of diabetes,” the researchers emphasized. The study suggests targeting ALDH3B2 could replenish beta-cell mass, potentially addressing both type 1 and type 2 diabetes.
Challenges and Next Steps
While promising, the method faces hurdles. The transdifferentiated cells exhibited lower glucose-stimulated insulin production compared to natural beta cells, and the mechanism by which ALDH3B2 restricts duct cell plasticity remains unclear. Addressing these limitations will be important for improving conversion efficiency, promoting maturation, and advancing this strategy toward therapeutic application,
the team noted.
Future research will focus on identifying additional genes that, when targeted, could enhance the efficiency and functionality of the converted cells. The next step is either gene therapy or to find specific small molecules to inhibit this gene to see if we can achieve a similar—or even better—effect,
said Jian Li, a postdoctoral researcher at Harvard Medical School. The team also stresses the need for precise targeting to avoid off-target effects, as ALDH3B2 is active in multiple cell types.
The study underscores the potential of gene-editing technologies to transform diabetes care. By harnessing the body’s own cellular machinery, researchers may one day develop therapies that restore natural insulin regulation, reducing reliance on daily injections and improving quality of life for millions.